Concord Drugs Limited has intimated about a scheduled meeting of its Board of Directors pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board meeting is scheduled to be held on Monday, 10th August, 2026 at the Registered Office of the company located at Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511, Telangana, India.
The primary agenda of the meeting is to consider and approve the Un-audited (Standalone & Consolidated) financial results of the company for the quarter ended 30th June, 2026. The board may also transact such other business as may be considered necessary with the permission of the Chair.
In accordance with the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's equity shares has been closed for all designated persons and their immediate relatives. The trading window closure is effective immediately and shall remain closed until 48 hours after the declaration of the financial results.
The intimation is addressed to BSE Limited and references the company's Scrip Code: 538965 and ISIN: INE858L01010.